Evaluation of Neuropsychiatric outcomes in patients hospitalized with COVID-19 in a nationwide Veterans Health Administration cohort.

Hospitalized patients with COVID-19 have an increased risk of developing psychiatric symptoms associated with post-COVID-19 syndrome. We aimed to evaluate the impact of COVID-19 hospitalization on neuropsychiatric healthcare utilization as well as new-onset depression and dementia. This nationwide, retrospective, observational cohort study included hospitalized COVID-19 patients aged 18 years or older across the Veterans Health Administration database from January 1st, 2020 through January 1st, 2022. The COVID-19 group consisted of patients hospitalized with COVID-19 with a positive test within seven days of the hospitalization. The control group consisted of patients hospitalized for reasons other than COVID-19 without a prior positive test or during the study duration. Propensity scores were utilized for 1:1 matching. This study included 50,805 patients in each matched cohort. Average patient population was 69 years old with ∼93 % male. The primary outcome of psychiatry-related hospitalization incidence rates were significantly higher in the COVID-19 group at both 90 days and 180 days. There was also a significant increase in the incidence outpatient mental health visits at 180 days in the COVID-19 cohort. Significantly higher risk of new-onset depression and new-onset dementia in the COVID-19 hospitalization group at 180 days as compared to the non-COVID-19 cohort was noted.

CHAnges in Diuretic Medication Prescribing and Surrogate Laboratory Parameters After Initiating EmpagliflOziN in Veterans (CHAMPION Cohort Study).

BACKGROUND AND OBJECTIVES: Sodium-glucose cotransporter type 2 inhibitors have evolved into a novel drug class utilized for reductions in cardiovascular risk and heart failure hospitalization. We aimed to describe the impact of sodium-glucose cotransporter type 2 inhibitors on diuretic prescribing patterns and intermediate laboratory outcomes in patients with and without diuretic use. METHODS: This retrospective cohort study included patients taking empagliflozin as of 1 July, 2021. Patients were assigned to the intervention group if prescribed a diuretic concomitantly or a control group otherwise. The primary outcome was the impact of empagliflozin on diuretic prescribing (i.e., no change, discontinuation, decrease, increase). Secondary outcomes were change in weight, hemoglobin A1c, estimated glomerular filtration rate, hemoglobin, hematocrit, blood pressure, and electrolytes at 90 and 180 days. Mean differences were compared using the t-test between groups or the paired t-test within groups. Patients without diuretic use were matched 1:1 to patients taking diuretics using propensity scores. RESULTS: This study included 1189 patients: 750 in the control group and 439 in the intervention group. After propensity score matching, baseline characteristics were well balanced. Of the 439 patients in the intervention group, 118 had changes in the diuretic regimen. There were 131 changes: 109 (83.2%) discontinuations, 13 (9.92%) decreases, and nine (6.87%) increases. The mean furosemide equivalent loop dose was reduced after empagliflozin initiation (50.62 mg vs 43.13 mg; p < 0.001). Among all patients, there was a decrease in weight (p = 0.01), estimated glomerular filtration rate (p < 0.001), and hemoglobin A1c (p < 0.001). There was an increase in hemoglobin (p < 0.001), hematocrit (p < 0.001), and magnesium (p < 0.001). In the propensity score-matched cohort, there was a significant reduction from baseline in mean weight in the intervention group compared with the control group (p < 0.001). CONCLUSIONS: This hypothesis-generating study suggests that sodium-glucose cotransporter type 2 inhibitors may lower diuretic requirements, further supported by a reduction in weight in the intervention cohort.

A Retrospective Comparison of Intravenous Opioid Use for Abdominal Pain in the Emergency Department After Implementation of Order Set Restriction.

BACKGROUND: This study was developed to provide insight into the effects of an i.v. opioid order set on prescribing of i.v. opioids in the emergency department (ED) for nontraumatic, unspecified abdominal pain. Research is needed in this area to catalyze more consistent and evidence-based i.v. opioid prescribing. OBJECTIVE: This study aimed to show the impact of an i.v. opioid order set restriction. Secondary objectives were the change in ED length of stay, change in pain score, total i.v. opioid morphine milligram equivalents, and number of i.v. opioid doses. METHODS: Patients included in the study visited the ED with a relevant ICD-10-CM diagnosis code for nontraumatic, unspecified abdominal pain 3 months prior to or 3 months after the restriction. A sample size of 596 patients was calculated for 80% power to identify a 25% difference in the primary outcome. RESULTS: There was a statistically significant decrease in i.v. opioid administration after the restriction (44.2% preintervention, 23.2% postintervention; p < 0.001). Mean length of stay decreased from 6.6 h to 6.2 h (p < 0.05). There was no statistically significant difference in pain scores. Oral opioid use increased significantly (20.5% preintervention, 31.7% postintervention; p < 0.001); therefore, combined i.v. and oral opioid use did not change significantly. CONCLUSIONS: The restriction correlated with a decrease in i.v. opioids. Pain control was not diminished as a result of the restriction. The results of this study may be used to generate hypotheses for comparing different modes of pain management in the ED in this patient population and others. Future studies should continue to evaluate the impact of oral vs. i.v. opioids.